This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
A Slew Of Q3 Earnings
by Zacks Equity Research
A Slew Of Q3 Earnings
Big Morning of Q3 Earnings Beats
by Mark Vickery
Most major companies reporting before the opening bell today have outperformed expectations -- in some cases by a wide margin.
Lilly (LLY) Beats on Q3 Earnings, Explores Sale of Elanco
by Zacks Equity Research
Eli Lilly (LLY) beat estimates for both sales and earnings in Q3 and upped its 2017 outlook. Separately, the company said that it is exploring strategic alternatives for the Elanco Animal Health business.
Eli Lilly (LLY) Tops Q3 Earnings & Sales, Ups 2017 View
by Zacks Equity Research
Eli Lilly (LLY) beat estimates for both sales and earnings in Q3 and upped its 2017 outlook. Separately, the company said that it is exploring strategic alternatives for the Elanco Animal Health business.
Will Merck (MRK) Keep the Earnings Streak Alive in Q3?
by Zacks Equity Research
Merck's (MRK) new products like Keytruda, Zepatier and Bridion are likely to drive sales in Q3. However, headwinds remain in the form genericization of key drugs and increasing competition.
Key Predictions for Q3 Earnings Reports of LLY, BIIB, NVS
by Zacks Equity Research
The pharma/biotech industry has seen a solid start to the Q3 earnings season as evident from J&J's solid results. Let's see if the other leading players -- Lilly, Biogen and Novartis -- follow suit.
Pharma Stock Roundup: Beat & Raise Quarter from J&J, Allergan Hit by Restasis Ruling
by Arpita Dutt
Johnson & Johnson's (JNJ) Q3 earnings results were the key highlight this week with the company reporting strong results and raising its outlook.
Can ImmunoGen's Key Pipeline Cancer Candidate Drive Growth?
by Zacks Equity Research
Though ImmunoGen (IMGN) is progressing with lead ovarian cancer candidate, mirvetuximab soravtansine, the company is likely to face stiff market competition from established products upon approval.
Teva Submits BLA to FDA for Migraine Candidate Fremanezumab
by Zacks Equity Research
Teva Pharma (TEVA) submits BLA seeking approval for its pipeline candidate, Fremanezumab, as a preventive treatment for migraine in the United States.
Novartis Reports Positive Results on Thrombocytopenia Drug
by Zacks Equity Research
Novartis AG (NVS) announced encouraging results on Revolade from the EXTEND study.
What to Expect from Big Pharmas After J&J's Solid Q3 Results?
by Zacks Equity Research
Large-cap pharmas are expected to report encouraging third-quarter results, following J&J's earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter.
Eli Lilly (LLY) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Eli Lilly and Company's (LLY) new drugs like Trulicity, Taltz and Jardiance have been performing well. Let's see if these along with its older products lead the company to an earnings beat.
Cancer Space Update: Lung & Breast Cancer Studies in Focus
by Zacks Equity Research
While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.
Lilly's Verzenio Gets Priority Review in First-Line Setting
by Zacks Equity Research
Eli Lilly and Company (LLY) announced that the FDA has granted priority review to its new drug application for Verzenio (abemaciclib) for the first-line treatment of advanced breast cancer.
Pharma Stock Roundup: Pfizer Mulls Options for Consumer Healthcare, LLY's Pipeline Setback
by Arpita Dutt
Pfizer (PFE) is looking at strategic options for its Consumer Healthcare business while Merck announced that it won't be seeking approval for its CETP inhibitor.
IDEX (IEX) To Report Q3 Earnings: What's in the Cards?
by Zacks Equity Research
For the third quarter, IDEX's (IEX) revenues are likely to be affected by the volatility in the market as it procures substantial amount of raw materials and components from suppliers across the globe.
Merck Will Not Seek Approval for CETP Inhibitor Anacetrapib
by Zacks Equity Research
Merck (MRK) is not seeking approval for its CETP inhibitor anacetrapib, which it had developed for cholesterol management.
Lilly's (LLY) Verzenio Fails in Phase III Lung Cancer Study
by Zacks Equity Research
Lilly's breast cancer drug, Verzenio, failed to achieve primary endpoint in a phase III study evaluating the drug as monotherapy in advanced lung cancer patients.
Seattle Genetics Begins Phase II Study of Cancer Candidate
by Zacks Equity Research
Seattle Genetics (SGEN) and Astellas Pharma initiate phase II study-EV-201 of enfortumab vedotin for patients with locally advanced or metastatic urothelial cancer.
5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings
by Arpita Dutt
Here is a look at 5 pharma and biotech stocks including Pfizer (PFE) that are expected to post a positive earnings surprise in Q3.
Cancer Space Last Week Update: Pipeline Expansion in Focus
by Zacks Equity Research
Last week, a few companies in the cancer segment entered deals for expanding their portfolio. Another key development was a ruling in favor of a major cancer drug by the U.S. patent office.
Pharma Stock Roundup: Mylan Up, Teva Down on Copaxone News, Lawmakers Question Allergan Deal
by Arpita Dutt
The FDA approval of Mylan's (MYL) generic version of Teva's Copaxone was the main news this week. Allergan was also in the headlines related to its deal with the Saint Regis Mohawk Tribe.
Lilly Wins Favorable Ruling From U.S. PTO in Alimta Dispute
by Zacks Equity Research
Lilly (LLY) has received a favorable ruling from the U.S. PTO in a dispute related to vitamin regimen patent on its key cancer drug, Alimta.
4 Large-Cap Drug Stocks to Buy on Solid Momentum Ahead of Q3
by Zacks Equity Research
The Large Cap Pharmaceuticals industry has gained 20.7% year to date, outpacing 14.7% gain for the S&P 500.
Johnson & Johnson Files sNDA for Label Expansion of Invokana
by Zacks Equity Research
Johnson & Johnson (JNJ) filed a supplemental New Drug Application to the FDA for the label expansion of Invokana (canagliflozin) to reduce the risk of major adverse cardiovascular events in adults with type II diabetes.